ODONATE, INC. You should read the following discussion and analysis of our financial condition
and results of operations together with our condensed financial statements and
accompanying notes included in this Quarterly Report on Form 10-Q and our
audited financial statements and accompanying notes included in our Annual
Report on Form 10-K for the year ended
Forward-looking Statements
This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of the federal securities laws, and such statements may involve substantial risks and uncertainties. All statements, other than statements of historical facts included in this Quarterly Report on Form 10-Q, including, but not limited to, statements concerning: expectations regarding our future expenses, potential liabilities relating to litigation and financing needs; and other information referred to under this section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations," are forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "design," "estimate," "predict," "potential," "plan," "anticipate," "target," "forecast" or the negative of these terms and similar expressions intended to identify forward-looking statements. Forward-looking statements are not historical facts and reflect our current views with respect to future events. Forward-looking statements are also based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements.
There are a number of risks, uncertainties and other important factors that
could cause our actual results to differ materially from the forward-looking
statements contained in this Quarterly Report on Form 10-
Company Overview
We are a pharmaceutical company formerly focused on the development of
tesetaxel, an investigational, orally administered chemotherapy agent that
belongs to a class of drugs known as taxanes, which are widely used in the
treatment of cancer. In
14
--------------------------------------------------------------------------------
Results of Operations
The following table summarizes our results of operations for each of the periods
below (in thousands):
Three Months Ended Six Months Ended
June 30, June 30,
2021 2020 2021 2020
Research and development expense
$ 39 $ 104 $ 89 $ 762
Research and Development Expense
All of our research and development expense incurred through
The following table summarizes our research and development expense for each of the periods below (in thousands):
Three Months Ended Six Months Ended
June 30, June 30,
2021 2020 2021 2020
Non-personnel expense:
Clinical development $ 7,557 $ 19,542 $ 23,212 $ 36,077
Other 348 664 758 1,149
Total non-personnel expense 7,905 20,206 23,970 37,226
Personnel expense:
Restructuring expense 5,708 - 11,173 -
Salaries, bonuses and benefits 3,932 8,260 11,501 16,885
Equity-based compensation expense 1,080 2,311 2,909 4,613
Total personnel expense 10,720 10,571 25,583 21,498
Total research and development expense
Research and development expense was
General and Administrative Expense
General and administrative expense includes non-personnel and personnel-related expense. Nonpersonnel-related expense includes expense related to: (i) professional fees for legal, patent, consulting, accounting and audit services; (ii) insurance; and (iii) facilities and information technology. Personnelrelated expense includes expense related to salaries, bonuses and benefits, restructuring expense and equity-based compensation for personnel engaged in finance and administrative functions. We expect our general and administrative expense to decrease significantly due to the discontinuation of development of tesetaxel and winddown of tesetaxel-related operations.
15
--------------------------------------------------------------------------------
The following table summarizes our general and administrative expense for each of the periods below (in thousands):
Three Months Ended Six Months Ended
June 30, June 30,
2021 2020 2021 2020
Non-personnel expense $ 1,914 $ 1,486 $ 3,629 $ 2,928
Personnel expense:
Salaries, bonuses and benefits 791 981 1,679 2,129
Restructuring expense 465 - 482 -
Equity-based compensation expense 259 284 529 568
Total personnel expense 1,515 1,265 2,690 2,697
Total general and administrative expense
General and administrative expense was
Other Income, Net
Other income, net consists primarily of interest income generated from cash held in savings accounts. Other income, net also includes losses on disposal of property and equipment and gains and losses on foreign currency transactions.
Other income, net was
Liquidity and Capital Resources
As of
Net cash used in operating activities was
In
We expect to finance our future cash needs with cash on hand. If necessary or appropriate, we may raise additional capital through equity offerings, debt financings, collaborations, strategic partnerships or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants
16
--------------------------------------------------------------------------------
limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic partnerships or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property on terms that may not be favorable to us.
Contractual Obligations and Commitments
See Note 5 to the condensed financial statements included in Item 1 of this Quarterly Report on Form 10-Q, under the subheading "Lease Commitments," for information regarding our material lease agreements and Note 9 for information regarding our license agreement with Daiichi Sankyo Company, Limited for rights to tesetaxel.
Off-Balance Sheet Arrangements
During the periods presented, we did not have, nor do we currently have, any
off-balance sheet arrangements as defined under the rules of the
Jumpstart Our Business Startups Act
We are an emerging growth company, as defined in the Jumpstart Our Business
Startups Act of 2012 (the "JOBS Act"). Under this act, an emerging growth
company can delay the adoption of new or revised accounting standards issued
subsequent to the enactment of the JOBS Act until those standards would
otherwise apply to private companies. We have irrevocably elected not to avail
ourselves of this exemption from new or revised accounting standards and,
therefore, will be subject to the same new or revised accounting standards as
other public companies that are not emerging growth companies. However, we
intend to rely on other exemptions provided by the JOBS Act, including without
limitation, an exemption from the auditor attestation requirements of
Section 404(b) of the Sarbanes-Oxley Act of 2002, as amended. We will remain an
emerging growth company until
Critical Accounting Policies and Significant Judgments and Estimates
We believe the estimates, assumptions and judgments involved in the accounting
policies described in "Management's Discussion and Analysis of Financial
Condition and Results of Operations" in Item 7 of our Annual Report on Form 10-K
for the year ended
Recent Accounting Pronouncements
See Note 2 to our condensed financial statements included in Item 1 of this Quarterly Report on Form 10-Q.
17
--------------------------------------------------------------------------------
© Edgar Online, source
